Wedbush Maintains Outperform, $13 Target on Anacor

Wedbush reiterates its Outperform rating and $13 target price on Anacor Pharmaceuticals

, reflecting positive phase 2a data for both ‘2728 and ‘2898 in Atopic Dermatitis. Wedbush says, “Anacor released statistically significant top-line efficacy results for AN2728 and AN2898 from its Phase IIa trial in atopic dermatitis. Recall that this trial was a 6-week trial that enrolled 46 patients (randomized 1:1) comparing active agent to vehicle, with a primary endpoint of proportion of patients showing an improvement in lesion score (Atopic Dermatitis Severity Index, ADSI). Of the 46 patients, 25 were in the ‘2728 arm and 21 in the ‘2898 arm.” ANAC closed at $5.83 per share on Monday.